Outlook for 2024
For fiscal year 2024, the Company reaffirmed full year revenue guidance, which is expected to be in the range of $200 million to $205 million.
Standard BioTools Reaffirms Guidance
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.